Telepath: Understanding Users from a Human Vision Perspective in Large-Scale Recommender Systems

Designing an e-commerce recommender system that serves hundreds of millions of active users is a daunting challenge. From a human vision perspective, there're two key factors that affect users' behaviors: items' attractiveness and their matching degree with users' interests. This paper proposes Telepath, a vision-based bionic recommender system model, which understands users from such perspective. Telepath is a combination of a convolutional neural network (CNN), a recurrent neural network (RNN) and deep neural networks (DNNs). Its CNN subnetwork simulates the human vision system to extract key visual signals of items' attractiveness and generate corresponding activations. Its RNN and DNN subnetworks simulate cerebral cortex to understand users' interest based on the activations generated from browsed items. In practice, the Telepath model has been launched to JD's recommender system and advertising system. For one of the major item recommendation blocks on the JD app, click-through rate (CTR), gross merchandise value (GMV) and orders have increased 1.59%, 8.16% and 8.71% respectively. For several major ads publishers of JD demand-side platform, CTR, GMV and return on investment have increased 6.58%, 61.72% and 65.57% respectively by the first launch, and further increased 2.95%, 41.75% and 41.37% respectively by the second launch.Comment: 8 pages, 11 figures, 1 tabl

Spatially resolved Spectro-photometry of M81: Age, Metallicity and Reddening Maps

In this paper, we present a multi-color photometric study of the nearby spiral galaxy M81, using images obtained with the Beijing Astronomical Observatory 60/90 cm Schmidt Telescope in 13 intermediate-band filters from 3800 to 10000{\AA}. The observations cover the whole area of M81 with a total integration of 51 hours from February 1995 to February 1997. This provides a multi-color map of M81 in pixels of 1\arcsec.7 \times 1\arcsec.7. Using theoretical stellar population synthesis models, we demonstrate that some BATC colors and color indices can be used to disentangle the age and metallicity effect. We compare in detail the observed properties of M81 with the predictions from population synthesis models and quantify the relative chemical abundance, age and reddening distributions for different components of M81. We find that the metallicity of M81 is about $Z=0.03$ with no significant difference over the whole galaxy. In contrast, an age gradient is found between stellar populations of the central regions and of the bulge and disk regions of M81: the stellar population in its central regions is older than 8 Gyr while the disk stars are considerably younger, $\sim 2$ Gyr. We also give the reddening distribution in M81. Some dust lanes are found in the galaxy bulge region and the reddening in the outer disk is higher than that in the central regions.Comment: Accepted for publication in AJ (May 2000 issue). 27 pages including 6 figures. Uses AASTeX aasms4 styl

Intermediate-band Surface Photometry of the Edge-on Galaxy: NGC 4565

We present a deep, 42.79 hr image of the nearby, edge-on galaxy NGC 4565 in the Beijing-Arizona-Taipei-Connecticut (BATC) 6660A band using the large-format CCD system on the 0.6m Schmidt telescope at the Xinglong Station of the National Astronomical Observatories of China (NAOC). we obtain a final image that is calibrated to an accuracy of 0.02 mag in zero point, and for which we can measure galaxy surface brightness to an accuracy of 0.25 mag at a surface brightness at 27.5 mag arcsec^-2 at 6660A, corresponding to a distance of 22 kpc from the center of the disk. The integrated magnitude of NGC4565 in our filter is m6660=8.99 (R magnitude of 9.1) to a surface brightness of 28 mag arcsec-2. We analyze the faint outer parts of this galaxy using a two-dimensional model comprised of three components: an exponential thin disk, an exponential thick disk, and a power-law halo. A total of 12 parameters are included in our model. We determine the best values of our model parameters via 10,000 random initial values, 3,700 of which converge to final values. The thin disk and thick disk parameters we determine here are consistent with those of previous studies of this galaxy. However, our very deep image permits a better determination of the power law fit to the halo, constraining this power law to be between r^-3.2 and r^-4.0, with a best fit value of r^-3.88. We find the axis ratio of the halo to be 0.44 and its core radius to be 14.4 kpc (for an adopted distance of 14.5 Mpc).Comment: 34 pages, 11 figures, will appear in March 2002 of A

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)